First‐Dose Methylphenidate‐Induced Changes in the Anti‐Saccade Task Performance and Outcome in Adults with Attention‐Deficit/Hyperactivity Disorder

Objective We examined whether the anti‐saccade task (AST) performance after the first methylphenidate (MPH) dose could be associated with subsequent clinical outcome in adults with attention‐deficit/hyperactivity disorder (ADHD). Methods Ninety‐seven drug‐naive DSM‐5 ADHD adults participated in this...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fabrice Duval, Alexis Erb, Marie‐Claude Mokrani, Thomas Weiss, Roberta Carcangiu
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
Acceso en línea:https://doaj.org/article/0a2c861d2a6a4175a4959ca69d172432
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Objective We examined whether the anti‐saccade task (AST) performance after the first methylphenidate (MPH) dose could be associated with subsequent clinical outcome in adults with attention‐deficit/hyperactivity disorder (ADHD). Methods Ninety‐seven drug‐naive DSM‐5 ADHD adults participated in this study. The AST parameters were measured at baseline, after the first MPH‐dose (10 mg orally), and 6 months after chronic MPH treatment. Results were compared with those of 50 healthy control (HC) subjects. Results At baseline, ADHDs showed longer saccadic reaction times and more direction errors than HCs (both p < 0.00001). Acute and chronic MPH administration resulted in normalization of the AST performances. Multivariate regression analysis after adjusting for age, sex, weight, and severity of symptoms at baseline, revealed that a low percentage of direction errors after the first MPH‐dose (i.e., ≤10%) could predict remission at month 6 (OR: 5.84; 95% CI: 2.00–17.11; p = 0.001). Conclusions Our findings indicate that: (1) impairments of motor planning and response inhibition in adults with ADHD are improved with MPH, and (2) a low direction error percentage after the first MPH‐dose may be an independent predictor of remission. ClinicalTrials.gov identifier: NCT03411434